Episode 097: Treatment of Relapsed/Refractory CLL
The Fellow on Call: The Heme/Onc Podcast
00:00
Navigating Toxic Therapies and Poor Prognoses in CLL
This chapter examines the withdrawal of idelalisib from the market due to safety issues and its ineffectiveness compared to standard therapies for CLL. It highlights the critical nature of Richter's transformation in CLL and the increasing importance of patient preferences and MRD-guided treatment approaches.
Transcript
Play full episode
